Friday 28 September 2018

Bioherbicides Market Size Worth $4.14 Billion by 2024 | Key Industry participants Marrone Bio Inventions, Fitz Chem Corporation


The global bioherbicides market size is expected to reach USD 4.14 billion by 2024, according to a new report by Grand View Research, Inc. The market is estimated to expand at a strong CAGR of 15.7% during the forecast period. Increasing preferences for organic farming along with rising consumption of eco-friendly weed control products is projected to drive the market in the near future.
Innovations in organic farming practices for sustainable crop cultivation are also expected to bolster the market growth over the forecast period. Shifting consumer preference toward greener and nutritional diet is fueling the demand for organically produced food grains and vegetables, which, in turn, will boost the market growth.
Bioherbicide products are also used in gardening, maintenance of golf course, and clearing of railway tracks. This is expected to further contribute toward the industry development in turf and ornament sector. Various regulatory norms and policies to promote organic farming are projected to increase product demand in the North America and Europe regions. However, availability of cheap, chemical-based herbicides may hinder the market growth.
Browse Research Report on Bioherbicides Market:

Further key findings from the study suggest:

·         The global bioherbicides market was valued at USD 1. 28 billion in 2016 and is anticipated to reach USD 4.14 billion by 2024, expanding at a CAGR of 15.7% over the forecast years
·         Fruits and vegetables accounted for over 27% of the global industry in 2015 and emerged as the largest application segment due to extensive product usage
·         North America led the global market in 2015 with a demand share of 29.5%. It is estimated to expand further on account of government initiatives and high consumer awareness about health and environmental issues
·         Asia Pacific is anticipated to witness the highest CAGR of 16.1% in the coming years. Product demand in Australia is anticipated to significantly contribute to the growth of this region
·         Key companies operating in the industry are Bioherbicides Australia (BHA); HerbaNatur Inc.; Hindustan Biotech Ltd.; Fitz Chem Corp.; Marrone Bio Innovations Emery Oleochemicals; Engage Agro USA; and Mycologic, Inc.

View more reports of this category by Grand View Research at
Grand View Research has segmented the global bioherbicides market on the basis of application and region:
Bioherbicides Application Outlook (Revenue, USD Million, 2014 - 2024)
·         Grains and Cereals
·         Oil Seeds
·         Fruits and Vegetables
·         Turf and Ornament
Bioherbicides Regional Outlook (Revenue, USD Million, 2014 - 2024)
·         North America
o    U.S
o    Canada
·         Europe
o    Germany
o    U.K.
·         Asia Pacific
o    India
o    China
o    Australia
·         Central & South America
o    Brazil
·         Middle East and Africa
o    Saudi Arabia

View press release of this research report by Grand View Research:


About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials, and healthcare.

For more information: www.grandviewresearch.com

Systemic Lupus Erythematosus Market Market Size Worth $3.08 Billion by 2025 | Key Industry participants Pfizer, Novartis



The global systemic lupus erythematosus market size is expected to reach USD 3.08 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 7.0% during the forecast period.Introduction of new biological therapies, which will add to treatment alternatives and medication costs, in the development pipeline is estimated to fuel revenue generation of the market. Certain new promising drugs that are currently in Phase III trials are anticipated to augment the market as these drugs may target the lupus nephritis patient subset with few effective alternatives and significant unmet needs to be met. This factor is likely to have a strong impact on the market as nearly 50.0% of SLE patients suffer with lupus nephritis.
Use of approved biologic, Benlysta, through clinical studies, has revealed drastic improvements and substantial decrease in consumption of anti-inflammatory glucocorticoids in moderate SLE cases. GSK’s current initiatives center on further increasing opportunities for Benlysta. The company is conducting indication expansion clinical trials, combination therapy studies with rituximab, and new product development, to widen opportunities for its therapy. In this direction, recent launch of Benlysta’s subcutaneous formulation in several countries is expected to boost the SLE market over the forecast period.
Browse Research Report on Systemic Lupus Erythematosus Market:

Further key findings from the study suggest:

·         North America was the major contributor for the SLE market revenue in 2017 and is anticipated to rise at a CAGR of 8.1% during the forecast period. This is due to availability of reimbursement and better healthcare infrastructure and accessibility to biologics.
·         Europe was ranked as the second largest regional market in the SLE market in 2017 and is expected to register a CAGR of 5.5% over the forecast period
·         Immunosuppressants held the largest share in the market in 2017 due to their low cost and high accessibility, whereas the biologics segment is projected to post the highest CAGR during the same period
·         In 2017, the oral segment held the dominant share of over 54.0% in the market, followed by the intravenous segment that requires trained medical personnel for administration. Over the forecast years, the latter is poised to expand at a CAGR of 10.4%
·         Key players in this space include GlaxoSmithKline, Roche, Pfizer, Novartis, Bayer, and Sanofi. By 2025, other companies such as ImmuPharma, Aurinia Pharmaceuticals, and Astra Zeneca are anticipated to enter the SLE market.

View more reports of this category by Grand View Research at

Grand View Research has segmented the global systemic lupus erythematosus market by drug class, route of administration, and region:
Systemic Lupus Erythematosus Drug Classes Outlook (Revenue, USD Million, 2014 - 2025)
·         NSAIDs
·         Corticosteroids
·         Antimalarials
·         Immunosuppressants
·         Biologics
Systemic Lupus Erythematosus Route of Administration Outlook (Revenue, USD Million, 2014 - 2025)
·         Oral
·         Intravenous
·         Subcutaneous
Systemic Lupus Erythematosus Regional Outlook (Revenue, USD Million, 2014 - 2025)
·         North America
o    U.S.
o    Canada
·         Europe
o    U.K.
o    Germany
o    France
o    Italy
o    Spain
o    Greece
o    Sweden
o    Norway
o    Poland
o    RoE
·         Asia Pacific
·         Latin America
o    Brazil
o    Mexico
o    Argentina
·         MEA
View press release of this research report by Grand View Research:

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials, and healthcare.

For more information: www.grandviewresearch.com

Thursday 27 September 2018

Novel Drug Delivery Systems Market Worth $26.6 Billion By 2025: Grand View Research, Inc.



According to a report by Grand View Research, Inc., global novel drug delivery systems(NDDS) in cancer therapy market is anticipated to value USD 26.61 billion by 2025. Growing requirement for advanced medical devices to avail better treatment is anticipated to propel demand for novel drug delivery systems. These systems are likely to protect drugs essential for cancer treatment from enzymatic and chemical degradation.  

Growing need for cancer therapeutic drugs owing to rising cases of cancer is expected to influence growth of market. Spreading awareness among patients regarding availability of alternative methods of cancer treatments can stimulate market growth.  Rising cases of cancer owing to unhealthy lifestyle is anticipated to influence growth of market. Increasing R&D investments to expand product pipeline and for regulatory approvals of new products can influence market growth. Supportive reimbursement scenarios in developed nations coupled with availability of research funding is likely to augment market growth during the forecast period (2014 to 2025).  

Full Research Report On Novel Drug Delivery Systems (NDDS) Analysis:  www.grandviewresearch.com/industry-analysis/novel-drug-delivery-systems-in-cancer-therapy

The NNDS in cancer therapy market can be segregated on the basis of product and region. Based on product, the market can be categorized into embolization particles and nanoparticles. In 2016, nanoparticles segment dominated the market and accounted of largest market share. It is anticipated to grow at similar pace during the forecast period. These type of drug delivery systems are expected to encapsulate various drugs and protect them from enzymatic and chemical degradation. In addition, they can provide long circulation half-lives, improved pharmacokinetics and reduced side effects. Moreover, these systems can also offer enhanced permeability to allow efficient delivery of drugs to cancer tissues.

Based on aforementioned properties, nanoparticles can replace conventional chemotherapy treatment attributed to less risk to healthy tissues and high efficiency. Nanoparticles can be categorized into micelles, liposomes, polymers, and other nanoparticles. Micelles and liposomes are likely to be used for DNA delivery & targeting and can increase drug efficacy. In 2016, liposomes segment held for largest market share under nanoparticles segment. It is expected to grow at similar pace during the forecast period.   

Browse More Reports Of This Category By Grand View Research At: www.grandviewresearch.com/industry/medical-devices


On the contrary, embolization particles segment can be classified further into liquid emboli, PVA particles, drug eluting beads, and other embolization particles. These particles can be injected into small vessels providing blood to cancer cells. Such procedures can allow easy surgical reception of cancer cells resulting from reduced blood loss.  

Regional segmentation includes Europe, North America, Asia Pacific, Latin America, and Middle East and Africa. In 2016, North America region dominated the market and accounted for 36.8% revenue share. Increasing number of research activities to develop new therapies can fuel growth of market in the region. In addition, growing awareness availability of novel drugs attributed to promotional and marketing activities of manufacturers is anticipated to propel market growth. Moreover, growing budget for novel drug discovery coupled with increasing number of food and drug administration (FDA) approvals can also fuel market growth in the region.

On the contrary, European market followed North America and stood second in terms of revenue share in 2016. It is expected to witness significant growth during the forecast period attributed to growing healthcare expenditure. High prevalence of cancer patients coupled with rise in research funding for cancer treatments can fuel market growth. Many local organizations in United Kingdom and Germany are expected to fund new technologies, which in turn can influence market growth in the region.

In Asia Pacific, the market is expected to grow at fastest rate during the forecast period. Rising cases of cancer in China and Japan owing to increasing geriatric population can stimulate market growth. In addition, increasing number of research activities coupled with growing awareness regarding availability of new cancer therapies can augment growth of market in the region.

Some of the leading companies offering NNDS in cancer therapy are Merrimack Pharmaceuticals, Inc.; Teva Pharmaceutical Industries Limited; Johnson & Johnson Services, Inc.; Samyang Biopharmaceuticals Corporation; and Celgene Corporation. Geographic expansions, frequent product launches, and distribution agreements to increase customer base are likely to be key strategies players can undertake to expand their market share. In addition, companies are likely to invest in R&D activities to develop new and innovative NDDS systems in cancer therapy to expand their product portfolio.
Grand View Research, Inc. has segmented the novel drug delivery systems (NDDS) in cancer therapy market on the basis of product and region:
 Product Outlook (Revenue, USD Million, 2014 - 2025)
  • Nanoparticles
    • Liposomes
    • Polymers
    • Micelles
    • Other nanoparticles
  • Embolization particles
    • PVA particles
    • Drug eluting beads
    • Liquid emboli
    • Other embolization particles
Regional Outlook (Revenue, USD Million, 2014 - 2025)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
  • Asia Pacific
    • China
    • Japan
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • South Africa

Browse Press Release of this Report:

About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com/


Nitrile Butadiene Rubber (NBR) Market | Industry Growth, Trends and Forecast Up to 2025 | Key Industry Players Lanxess AG, Kumho Petrochemical Co.



The global nitrile Butadiene Rubber (NBR) market is expected to reach USD 2.59 billion by 2025, growing at a CAGR of 3.3%, according to a new report by Grand View Research, Inc. Asia Pacific is expected to provide ample scope for the industry growth of NBR by the end of 2025. China, India, and Southeast Asian countries are likely to reflect a strong growth scenario in the future.
NBR is one of the versatile synthetic rubbers that is highly consumed in high end applications, which require the product to be highly sustainable to varying operational and climatic conditions. This makes the product suitable for use in a wide array of industries.
NBR demand in China and India is expected to be driven by significant industrial developments of key end-use sectors in the region including automotive & transportation, metallurgy & mining, oil & gas, equipment & machinery, and medical sectors. These recent developments have propelled the requirements of mechanical goods such as cables, belts, gaskets, and seals.
Rise in the consumer disposable income and purchasing power in ASEAN countries including Indonesia and Thailand, has led to a rapid growth of the automotive industry as well as a strong increase in aftermarket activities. Moreover, increase in the healthcare expenditure in these countries is another key factor that is expected to boost the consumption of nitrile gloves by 2025.
Full Research Report On Nitrile Butadiene Rubber (NBR) Market Analysis:

Further key findings from the report suggest:
·         In terms of volume, the seals & O-rings segment is expected to rise at a CAGR of 2.9% from 2017 to 2025. This category is expected to generate a market revenue of nearly US$ 491.3 million by the end of the forecast period.
·         Consumption of nitrile gloves is estimated to increase at the fastest growth rate over the years ahead, as a consequence of significant product utilization in the healthcare & hygiene sector
·         Wide production expanse particularly in China and India is likely to drive the NBR consumption in mechanical engineering applications including vibration dampening materials, impact machinery, pumps, hydraulic equipment, and compressors
·         Europe accounted for the second-largest revenue share of over 20.0% of the global market in 2016. CIS countries mainly Russia, are likely to witness fast paced industry growth owing to significant use of hoses, and seals & O-rings in the oil & gas sector.
·         Companies are aiming to strengthen their positions in the global industry through acquisition, technology licensing, and collaborations
·         In June 2014, Sinopec Corp jointly ventured with SIBUR, a Russian petrochemicals and gas processing company for the construction of a nitrile rubber plant with an annual production capacity of 50 kilo tons at the Shanghai Chemical Industry Park, Shanghai

Grand View Research has segmented the global nitrile butadiene rubber (NBR) market on the basis of product, application, and region:
Product Outlook (Volume, Kilo Tons; Revenue, USD Million, 2014 - 2025)
·         Hoses
·         Belts
·         Cables
·         Molded & Extruded Products
·         Seals & O-rings
·         Rubber Compounds
·         Adhesives & Sealants
·         Gloves
·         Foamed Products
·         Others
Application Outlook (Volume, Kilo Tons; Revenue, USD Million, 2014 - 2025)
·         Automotive
·         Mechanical Engineering
·         Oil & Gas
·         Metallurgy & Mining
·         Construction
·         Medical
·         Others
Regional Outlook (Volume, Kilo Tons; Revenue, USD Million, 2014 - 2025)
·         North America
o    U.S.
·         Europe
o    Germany
o    UK
o    CIS
·         Asia Pacific
o    China
o    India
·         Central & South America
o    Brazil
·         Middle East & Africa
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com